Neurocrine Biosciences' CEO Presents At Deutsche Bank 37th Annual Health Care Conference (Transcript)

Neurocrine Biosciences, Inc. (NBIX)

Deutsche Bank 37th Annual Health Care Conference Call

May 09, 2012 11:20 am ET

Executives

Kevin C. Gorman – President and Chief Executive Officer

Analysts

Navdeep Singh – Deutsche Bank Securities, Inc.

Presentation

Navdeep Singh – Deutsche Bank Securities, Inc.

Hey, good morning everyone and thanks for attending the third and final day of the 37th Annual Deutsche Bank Health Care Conference. My name is Navdeep Singh and I’m one of the Deutsche Bank Biotechnology Analyst, and up next we have Neurocrine Biosciences and representing the company is Kevin Gorman, Chief Executive Officer. Kevin?

Kevin C. Gorman

Thank you, Navdeep and thank you to Deutsche Bank for inviting us to the conference. Before I start out, I’ll direct you to our Safe Harbor statement and our resent SEC fillings for an exhaustive detailing of the risk factors because I will be making forward looking statements today.

So I’m going to basically talk about our two main programs at Neurocrine today. The first one being our elagolix program, a small molecule GnRH Antagonists that we partnered with Abbott and Abbott now fully controls and runs this program.

The second program that I’ll be speaking about is our wholly-owned VMAT2 program for movement disorders. And so let’s start right in with the elagolix program. I usually never stop on this slide, but I will today because endometriosis is a condition that is characterized by at times extreme pain.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Inovio, Neurocrine, Alnylam

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Wall Street Closes Lower Amid Continued Global Worries